David J Kwiatkowski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5109312/publications.pdf

Version: 2024-02-01

422 papers	59,815 citations	553 126 h-index	1109 231 g-index
455 all docs	455 docs citations	455 times ranked	55180 citing authors

#	Article	IF	Citations
1	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell, 2017, 171, 540-556.e25.	13.5	1,742
2	Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing. Cell, 2012, 150, 1107-1120.	13.5	1,591
3	Identification of the Tuberous Sclerosis Gene TSC1 on Chromosome 9q34. Science, 1997, 277, 805-808.	6.0	1,550
4	Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA - Journal of the American Medical Association, 2014, 311, 1998.	3.8	1,386
5	Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 2013, 49, 243-254.	1.0	1,185
6	Caspase-3-Generated Fragment of Gelsolin: Effector of Morphological Change in Apoptosis. Science, 1997, 278, 294-298.	6.0	1,113
7	Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nature Genetics, 2016, 48, 607-616.	9.4	933
8	LKB1 modulates lung cancer differentiation and metastasis. Nature, 2007, 448, 807-810.	13.7	907
9	Mutational Analysis in a Cohort of 224 Tuberous Sclerosis Patients Indicates Increased Severity of TSC2, Compared with TSC1, Disease in Multiple Organs. American Journal of Human Genetics, 2001, 68, 64-80.	2.6	867
10	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Journal of Thoracic Oncology, 2013, 8, 823-859.	0.5	792
11	Reversal of learning deficits in a Tsc2+/â˜’ mouse model of tuberous sclerosis. Nature Medicine, 2008, 14, 843-848.	15.2	771
12	Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13571-13576.	3.3	744
13	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. European Urology, 2020, 77, 420-433.	0.9	741
14	Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 2013, 49, 255-265.	1.0	693
15	The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma. Cancer Cell, 2014, 26, 319-330.	7.7	665
16	A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Human Molecular Genetics, 2002, 11, 525-534.	1.4	580
17	Nonmuscle Actin-Binding Proteins. Annual Review of Cell Biology, 1985, 1, 353-402.	26.0	557
18	Actin-binding protein requirement for cortical stability and efficient locomotion. Science, 1992, 255, 325-327.	6.0	530

#	Article	IF	Citations
19	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports, 2018, 23, 313-326.e5.	2.9	523
20	Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790Mâ€“Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncology, 2018, 4, 1527.	3.4	522
21	Akt Stimulates Hepatic SREBP1c and Lipogenesis through Parallel mTORC1-Dependent and Independent Pathways. Cell Metabolism, 2011, 14, 21-32.	7.2	511
22	TBC1D7 Is a Third Subunit of the TSC1-TSC2 Complex Upstream of mTORC1. Molecular Cell, 2012, 47, 535-546.	4.5	509
23	Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science, 1992, 258, 1148-1152.	6.0	506
24	Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4129-4134.	3.3	498
25	Plasma and cytoplasmic gelsolins are encoded by a single gene and contain a duplicated actin-binding domain. Nature, 1986, 323, 455-458.	13.7	484
26	Human endothelial actin-binding protein (ABP-280, nonmuscle filamin): a molecular leaf spring.. Journal of Cell Biology, 1990, 111, 1089-1105.	2.3	482
27	Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nature Neuroscience, 2005, 8, 1727-1734.	7.1	469
28	mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. Journal of Clinical Investigation, 2011, 121, 2181-2196.	3.9	462
29	Hematopoietic Cell Regulation by Rac1 and Rac2 Guanosine Triphosphatases. Science, 2003, 302, 445-449.	6.0	446
30	Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function. Journal of Neuroscience, 2008, 28, 5422-5432.	1.7	445
31	Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. Journal of Clinical Investigation, 2003, 112, 1223-1233.	3.9	434
32	A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. Cancer Cell, 2017, 31, 820-832.e3.	7.7	433
33	Rapid turnover of actin in dendritic spines and its regulation by activity. Nature Neuroscience, 2002, 5, 239-246.	7.1	430
34	Hemostatic, inflammatory, and fibroblast responses are blunted in mice lacking gelsolin. Cell, 1995, 81, 41-51.	13.5	422
35	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discovery, 2018, 8, 1548-1565.	7.7	422
36	A Mouse Model of Tuberous Sclerosis: Neuronal Loss of Tsc1 Causes Dysplastic and Ectopic Neurons, Reduced Myelination, Seizure Activity, and Limited Survival. Journal of Neuroscience, 2007, 27, 5546-5558.	1.7	410

#	Article	IF	Citations
37	Updated Molecular Testing Guideline for theÂSelection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2018, 13, 323-358.	0.5	408
38	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors. Journal of Molecular Diagnostics, 2013, 15, 415-453.	1.2	397
39	Tuberin Regulates p70 S6 Kinase Activation and Ribosomal Protein S6 Phosphorylation. Journal of Biological Chemistry, 2002, 277, 30958-30967.	1.6	393
40	Mena Is Required for Neurulation and Commissure Formation. Neuron, 1999, 22, 313-325.	3.8	377
41	Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis. Cancer Biology and Therapy, 2003, 2, 471-476.	1.5	369
42	Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors. Journal of Clinical Oncology, 2010, 28, 835-840.	0.8	362
43	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. Journal of Thoracic Oncology, 2015, 10, 768-777.	0.5	357
44	An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nature Genetics, 2015, 47, 1067-1072.	9.4	354
45	Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nature Genetics, 2016, 48, 600-606.	9.4	352
46	Functions of gelsolin: motility, signaling, apoptosis, cancer. Current Opinion in Cell Biology, 1999, 11, 103-108.	2.6	347
47	Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Human Molecular Genetics, 2005, 14, R251-R258.	1.4	343
48	Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight, 2016, 1, e87062.	2.3	340
49	Tsc2+/â€“ mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. Journal of Clinical Investigation, 1999, 104, 687-695.	3.9	337
50	Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease. Nature Genetics, 1992, 2, 37-41.	9.4	334
51	Perivascular epithelioid cell neoplasms: pathology and pathogenesis. Human Pathology, 2010, 41, 1-15.	1.1	332
52	Astrocyte-specificTSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Annals of Neurology, 2002, 52, 285-296.	2.8	330
53	Molecular genetic advances in tuberous sclerosis. Human Genetics, 2000, 107, 97-114.	1.8	323
54	Tuberous Sclerosis: from Tubers to mTOR. Annals of Human Genetics, 2003, 67, 87-96.	0.3	321

#	Article	IF	Citations
55	PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. Journal of Clinical Investigation, 2007, 117, 730-738.	3.9	321
56	Filamin A (FLNA) is required for cell-cell contact in vascular development and cardiac morphogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19836-19841.	3.3	306
57	Enhanced motility in NIH 3T3 fibroblasts that overexpress gelsolin. Science, 1991, 251, 1233-1236.	6.0	301
58	Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. Journal of Clinical Investigation, 2003, 112, 1223-1233.	3.9	300
59	Loci Related to Metabolic-Syndrome Pathways Including LEPR,HNF1A, IL6R, and GCKR Associate with Plasma C-Reactive Protein: The Women's Genome Health Study. American Journal of Human Genetics, 2008, 82, 1185-1192.	2.6	299
60	Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Reports, 2016, 14, 2476-2489.	2.9	298
61	Coordinated regulation of protein synthesis and degradation by mTORC1. Nature, 2014, 513, 440-443.	13.7	292
62	Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer. New England Journal of Medicine, 2014, 371, 1426-1433.	13.9	290
63	Actin-binding proteins. Current Opinion in Cell Biology, 1991, 3, 87-97.	2.6	279
64	Rac1 Deletion in Mouse Neutrophils Has Selective Effects on Neutrophil Functions. Journal of Immunology, 2003, 170, 5652-5657.	0.4	276
65	Requirement of Rac1 in the development of cardiac hypertrophy. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7432-7437.	3.3	268
66	Mutational and Radiographic Analysis of Pulmonary Disease Consistent with Lymphangioleiomyomatosis and Micronodular Pneumocyte Hyperplasia in Women with Tuberous Sclerosis. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 661-668.	2.5	266
67	Two loci for Tuberous Sclerosis: one on 9q34 and one on 16p13. Annals of Human Genetics, 1994, 58, 107-127.	0.3	256
68	An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nature Medicine, 2008, 14, 979-984.	15.2	253
69	Somatic Mutations Activating the mTOR Pathway in Dorsal Telencephalic Progenitors Cause a Continuum of Cortical Dysplasias. Cell Reports, 2017, 21, 3754-3766.	2.9	247
70	Human gene for torsion dystonia located on chromosome 9q32-q34. Neuron, 1989, 2, 1427-1434.	3.8	246
71	Gelsolin Deficiency Blocks Podosome Assembly and Produces Increased Bone Mass and Strength. Journal of Cell Biology, 2000, 148, 665-678.	2.3	246
72	Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band l6p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. Genes Chromosomes and Cancer, 1995, 13, 295-298.	1.5	244

#	Article	IF	Citations
73	Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. American Journal of Human Genetics, 1996, 59, 400-6.	2.6	244
74	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. Journal of Molecular Diagnostics, 2018, 20, 129-159.	1.2	241
75	The Actin-Severing Protein Gelsolin Modulates Calcium Channel and NMDA Receptor Activities and Vulnerability to Excitotoxicity in Hippocampal Neurons. Journal of Neuroscience, 1997, 17, 8178-8186.	1.7	238
76	Tuberous sclerosis complex proteins control axon formation. Genes and Development, 2008, 22, 2485-2495.	2.7	238
77	Pathogenesis of Tuberous Sclerosis Subependymal Giant Cell Astrocytomas: Biallelic Inactivation ofTSC1orTSC2Leads to mTOR Activation. Journal of Neuropathology and Experimental Neurology, 2004, 63, 1236-1242.	0.9	237
78	Gelsolin is a downstream effector of rac for fibroblast motility. EMBO Journal, 1998, 17, 1362-1370.	3.5	236
79	mTOR-Raptor Binds and Activates SGK1 to Regulate p27 Phosphorylation. Molecular Cell, 2008, 30, 701-711.	4.5	236
80	Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia. Annals of Neurology, 2015, 77, 720-725.	2.8	235
81	Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatric Neurology, 2021, 123, 50-66.	1.0	230
82	Somatic LKB1 Mutations Promote Cervical Cancer Progression. PLoS ONE, 2009, 4, e5137.	1.1	229
83	Profilin I is essential for cell survival and cell division in early mouse development. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 3832-3836.	3.3	216
84	Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes and Development, 2005, 19, 1773-1778.	2.7	216
85	EGF receptor regulation of cell motility: EGF induces disassembly of focal adhesions independently of the motility-associated PLCÎ³ signaling pathway. Journal of Cell Science, 1998, 111, 615-624.	1.2	210
86	Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing. PLoS Genetics, 2015, 11, e1005637.	1.5	209
87	Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene, 2010, 29, 2346-2356.	2.6	207
88	Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. Journal of Clinical Investigation, 2010, 120, 103-114.	3.9	207
89	The transforming growth factor-Â1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Human Molecular Genetics, 2004, 13, 1649-1656.	1.4	203
90	Renal Cell Carcinoma in Tuberous Sclerosis Complex. American Journal of Surgical Pathology, 2014, 38, 895-909.	2.1	203

#	Article	IF	Citations
91	Cdc42 is required for PIP2-induced actin polymerization and early development but not for cell viability. Current Biology, 2000, 10, 758-765.	1.8	200
92	Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage disequilibrium, and haplotypes in three U.S. ethnic groups and exploratory caseâ€“control disease association studiesâ˜†â˜†This work was supported by Programs for Genomic Applications, Grant U01 HL66795, Innate Immunity in Heart, Lung and Blood Disease, from the National Heart, Lung and Blood Institute.. Genomics, 2003, 81, 85-91.	1.3	199
93	Association of CommonCRPGene Variants with CRP Levels and Cardiovascular Events. Annals of Human Genetics, 2005, 69, 623-638.	0.3	199
94	Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet, The, 2003, 361, 1348-1349.	6.3	196
95	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2016, 22, 2445-2452.	3.2	193
96	Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Molecular Cancer Therapeutics, 2009, 8, 742-753.	1.9	188
97	mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19384-19389.	3.3	187
98	Identification of critical functional and regulatory domains in gelsolin.. Journal of Cell Biology, 1989, 108, 1717-1726.	2.3	186
99	Single nucleotide polymorphisms in innate immunity genes: abundant variation and potential role in complex human disease. Immunological Reviews, 2002, 190, 9-25.	2.8	185
100	Attempted Replication of Reported Chronic Obstructive Pulmonary Disease Candidate Gene Associations. American Journal of Respiratory Cell and Molecular Biology, 2005, 33, 71-78.	1.4	185
101	Survey of Somatic Mutations in Tuberous Sclerosis Complex (TSC) Hamartomas Suggests Different Genetic Mechanisms for Pathogenesis of TSC Lesions. American Journal of Human Genetics, 2001, 69, 493-503.	2.6	182
102	Construction of a GT polymorphism map of human 9q. Genomics, 1992, 12, 229-240.	1.3	181
103	Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. American Journal of Pathology, 1996, 149, 1201-8.	1.9	179
104	Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12455-12460.	3.3	175
105	Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. Journal of Experimental Medicine, 2014, 211, 2249-2263.	4.2	170
106	Genomewide Linkage Analysis of Quantitative Spirometric Phenotypes in Severe Early-Onset Chronic Obstructive Pulmonary Disease. American Journal of Human Genetics, 2002, 70, 1229-1239.	2.6	168
107	Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications.. Journal of Clinical Oncology, 1998, 16, 2468-2477.	0.8	164
108	Efficacy of a rapamycin analog (CCI-779) and IFN-? in tuberous sclerosis mouse models. Genes Chromosomes and Cancer, 2005, 42, 213-227.	1.5	164

#	Article	IF	Citations
109	Critical Role for Hypothalamic mTOR Activity in Energy Balance. Cell Metabolism, 2009, 9, 362-374.	7.2	164
110	Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations. Human Genetics, 2007, 121, 389-400.	1.8	162
111	Genomic organization and biosynthesis of secreted and cytoplasmic forms of gelsolin. Journal of Cell Biology, 1988, 106, 375-384.	2.3	160
112	Chronic Activation of mTOR Complex 1 Is Sufficient to Cause Hepatocellular Carcinoma in Mice. Science Signaling, 2012, 5, ra24.	1.6	157
113	Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E1070-9.	3.3	155
114	Polymorphisms in Toll-Like Receptor 4 Are Not Associated with Asthma or Atopy-related Phenotypes. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 1449-1456.	2.5	154
115	The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutationsâ€"The Lung Cancer Mutation Consortium (LCMC2). Clinical Cancer Research, 2018, 24, 1038-1047.	3.2	154
116	Tuberous Sclerosis Complex Activity Is Required to Control Neuronal Stress Responses in an mTOR-Dependent Manner. Journal of Neuroscience, 2009, 29, 5926-5937.	1.7	151
117	Structure and biosynthesis of cytoplasmic and secreted variants of gelsolin. Journal of Biological Chemistry, 1984, 259, 5271-6.	1.6	147
118	Suppression of tumorigenicity in simian virus 40-transformed 3T3 cells transfected with alpha-actinin cDNA.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 383-387.	3.3	146
119	Dystonia gene in Ashkenazi Jewish population is located on chromosome 9q32-34. Annals of Neurology, 1990, 27, 114-120.	2.8	141
120	Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. Journal of Thoracic Oncology, 2019, 14, 876-889.	0.5	141
121	The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability. European Urology, 2019, 75, 961-964.	0.9	141
122	Coordinated regulation of platelet actin filament barbed ends by gelsolin and capping protein.. Journal of Cell Biology, 1996, 134, 389-399.	2.3	140
123	Comparisons of CapG and gelsolin-null macrophages. Journal of Cell Biology, 2001, 154, 775-784.	2.3	138
124	Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the <scp>EPISTOP</scp> Trial. Annals of Neurology, 2021, 89, 304-314.	2.8	137
125	Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung.. Journal of Clinical Oncology, 1995, 13, 1265-1279.	0.8	135
126	Neuroprotective effects of gelsolin during murine stroke. Journal of Clinical Investigation, 1999, 103, 347-354.	3.9	135

#	Article	IF	Citations
127	TOLL-like Receptor 10 Genetic Variation Is Associated with Asthma in Two Independent Samples. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 594-600.	2.5	133
128	Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Research, 2003, 63, 5173-7.	0.4	130
129	Delayed Retraction of Filopodia in Gelsolin Null Mice. Journal of Cell Biology, 1997, 138, 1279-1287.	2.3	129
130	FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis. Cancer Cell, 2010, 18, 472-484.	7.7	127
131	Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in LKB1-Mutant Lung Cancer. Cancer Discovery, 2013, 3, 870-879.	7.7	127
132	Perivascular Epithelioid Cell Tumors (PEComas) Harboring TFE3 Gene Rearrangements Lack the TSC2 Alterations Characteristic of Conventional PEComas. American Journal of Surgical Pathology, 2012, 36, 783-784.	2.1	125
133	Clinical and Genotype Studies of Cardiac Tumors in 154 Patients With Tuberous Sclerosis Complex. Pediatrics, 2006, 118, e1146-e1151.	1.0	124
134	Family-based association analysis of Î²2-adrenergic receptor polymorphisms in the childhood asthma management program. Journal of Allergy and Clinical Immunology, 2003, 112, 870-876.	1.5	119
135	Are Variants in the CAPN10 Gene Related to Risk of Type 2 Diabetes? A Quantitative Assessment of Population and Family-Based Association Studies. American Journal of Human Genetics, 2004, 74, 208-222.	2.6	119
136	Tsc2 Null Murine Neuroepithelial Cells Are a Model for Human Tuber Giant Cells, and Show Activation of an mTOR Pathway. Molecular and Cellular Neurosciences, 2002, 21, 561-574.	1.0	117
137	Genetic Loci Associated With Plasma Concentration of Low-Density Lipoprotein Cholesterol, High-Density Lipoprotein Cholesterol, Triglycerides, Apolipoprotein A1, and Apolipoprotein B Among 6382 White Women in Genome-Wide Analysis With Replication. Circulation: Cardiovascular Genetics, 2008, 1, 21-30.	5.1	117
138	Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. American Journal of Pathology, 1997, 151, 1639-47.	1.9	117
139	Catalytic Asymmetric Allylation of Ketones and a Tandem Asymmetric Allylation/Diastereoselective Epoxidation of Cyclic Enones. Journal of the American Chemical Society, 2004, 126, 12580-12585.	6.6	115
140	ADAM33 polymorphisms and phenotype associations in childhood asthma. Journal of Allergy and Clinical Immunology, 2004, 113, 1071-1078.	1.5	115
141	MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium. Journal of Thoracic Oncology, 2019, 14, 1666-1671.	0.5	115
142	Muscle is the major source of plasma gelsolin. Journal of Biological Chemistry, 1988, 263, 8239-43.	1.6	115
143	Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: Clinical and molecular correlates. International Journal of Cancer, 2013, 132, 1711-1717.	2.3	113
144	Tuberous Sclerosis Gene 2 Product Modulates Transcription Mediated by Steroid Hormone Receptor Family Members. Journal of Biological Chemistry, 1998, 273, 20535-20539.	1.6	112

#	Article	IF	Citations
145	Mosaicism in Tuberous Sclerosis as a Potential Cause of the Failure of Molecular Diagnosis. New England Journal of Medicine, 1999, 340, 703-707.	13.9	112
146	Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise. Clinical Cancer Research, 2015, 21, 4514-4524.	3.2	110
147	mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a Targetable Metabolic Vulnerability. Cancer Cell, 2017, 32, 624-638.e5.	7.7	109
148	Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex. Annual Review of Genomics and Human Genetics, 2019, 20, 217-240.	2.5	108
149	Genome-wide linkage analysis of severe, early-onset chronic obstructive pulmonary disease: airflow obstruction and chronic bronchitis phenotypes. Human Molecular Genetics, 2002, 11, 623-632.	1.4	106
150	Superiority of Denaturing High Performance Liquid Chromatography over single-stranded conformation and conformation-sensitive gel electrophoresis for mutation detection in TSC2. Annals of Human Genetics, 1999, 63, 383-391.	0.3	105
151	Analysis of TSC Cortical Tubers by Deep Sequencing of TSC1, TSC2 and KRAS Demonstrates that Small Secondâ€Hit Mutations in these Genes are Rare Events. Brain Pathology, 2010, 20, 1096-1105.	2.1	105
152	Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCIâ€™s Lung Cancer Mutation Consortium (LCMC).. Journal of Clinical Oncology, 2011, 29, CRA7506-CRA7506.	0.8	105
153	Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring <scp>BRAF</scp> mutations in the <scp>L</scp>ung <scp>C</scp>ancer <scp>M</scp>utation <scp>C</scp>onsortium. Cancer, 2015, 121, 448-456.	2.0	102
154	Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. Clinical Cancer Research, 2019, 25, 2458-2470.	3.2	102
155	Strong allelic association between the torsion dystonia gene (DYT1) andloci on chromosome 9q34 in Ashkenazi Jews. American Journal of Human Genetics, 1992, 50, 619-28.	2.6	100
156	bcl-2 Rearrangements in de novo diffuse large cell lymphoma. Association with distinctive clinical features. Cancer, 1993, 72, 231-236.	2.0	99
157	Distribution of KRAS^{G12C} Somatic Mutations across Race, Sex, and Cancer Type. New England Journal of Medicine, 2021, 384, 185-187.	13.9	98
158	The Introduction of Systematic Genomic Testing for Patients with Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1767-1774.	0.5	96
159	Role of the Tsc1-Tsc2 Complex in Signaling and Transport Across the Cell Membrane in the Fission Yeast Schizosaccharomyces pombe. Genetics, 2002, 161, 1053-1063.	1.2	96
160	Association of profilin with filament-free regions of human leukocyte and platelet membranes and reversible membrane binding during platelet activation.. Journal of Cell Biology, 1989, 109, 1571-1579.	2.3	94
161	Gelsolin in Complex with Phosphatidylinositol 4,5-Bisphosphate Inhibits Caspase-3 and -9 to Retard Apoptotic Progression. Journal of Biological Chemistry, 2000, 275, 3761-3766.	1.6	94
162	Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development. PLoS Genetics, 2016, 12, e1006242.	1.5	93

#	Article	IF	Citations
163	Caspase-3-induced gelsolin fragmentation contributes to actin cytoskeletal collapse, nucleolysis, and apoptosis of vascular smooth muscle cells exposed to proinflammatory cytokines. European Journal of Cell Biology, 1998, 77, 294-302.	1.6	92
164	Molecular Pathogenesis of Lymphangioleiomyomatosis. American Journal of Respiratory Cell and Molecular Biology, 2007, 36, 398-408.	1.4	91
165	Utilization of a whole genome SNP panel for efficient genetic mapping in the mouse. Genome Research, 2006, 16, 436-440.	2.4	89
166	Toll-like receptor 6 gene (TLR6): single-nucleotide polymorphism frequencies and preliminary association with the diagnosis of asthma. Genes and Immunity, 2004, 5, 343-346.	2.2	87
167	New applications and developments in the use of multiplex ligationâ€dependent probe amplification. Electrophoresis, 2008, 29, 4627-4636.	1.3	87
168	Genotype and cognitive phenotype of patients with tuberous sclerosis complex. European Journal of Human Genetics, 2012, 20, 510-515.	1.4	86
169	Role of gelsolin in the actin filament regulation of cardiac L-type calcium channels. American Journal of Physiology - Cell Physiology, 1999, 277, C1277-C1283.	2.1	85
170	Neuronal Tsc1/2 complex controls autophagy through AMPK-dependent regulation of ULK1. Human Molecular Genetics, 2014, 23, 3865-3874.	1.4	85
171	Human complement factor I: analysis of cDNA-derived primary structure and assignment of its gene to chromosome 4. Journal of Biological Chemistry, 1987, 262, 10065-71.	1.6	85
172	Human profilin. Molecular cloning, sequence comparison, and chromosomal analysis. Journal of Biological Chemistry, 1988, 263, 5910-5.	1.6	85
173	Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma. , 1999, 85, 47-57.		83
174	Regulation of Endothelial Nitric Oxide Synthase and Postnatal Angiogenesis by Rac1. Circulation Research, 2008, 103, 360-368.	2.0	82
175	Novel Mutations Detected in the TSC2 Hene From Both Sporadic and Familial TSC Patients. Human Molecular Genetics, 1996, 5, 249-256.	1.4	81
176	Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2. Nature Communications, 2017, 8, 14922.	5.8	80
177	Bronchioloalveolar carcinoma of the lung: Recurrences and survival in patients with stage I disease. Journal of Thoracic and Cardiovascular Surgery, 2001, 121, 42-47.	0.4	78
178	Association of defensin Î²-1 gene polymorphisms with asthma. Journal of Allergy and Clinical Immunology, 2005, 115, 252-258.	1.5	78
179	Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex. Human Genetics, 2010, 127, 573-582.	1.8	77
180	Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex. Human Molecular Genetics, 2014, 23, 2023-2029.	1.4	77

#	Article	IF	Citations
181	Neuronal gelsolin prevents apoptosis by enhancing actin depolymerization. Molecular and Cellular Neurosciences, 2004, 25, 69-82.	1.0	76
182	Novel Loci, Including Those Related to Crohn Disease, Psoriasis, and Inflammation, Identified in a Genome-Wide Association Study of Fibrinogen in 17 686 Women. Circulation: Cardiovascular Genetics, 2009, 2, 134-141.	5.1	76
183	Identification of VAV2 on 9q34 and its exclusion as the tuberous sclerosis gene TSC1. Annals of Human Genetics, 1995, 59, 25-37.	0.3	75
184	Cloning and chromosomal localization of the human cytoskeletal alpha-actinin gene reveals linkage to the beta-spectrin gene. American Journal of Human Genetics, 1990, 47, 62-72.	2.6	75
185	Isolation and properties of two actin-binding domains in gelsolin. Journal of Biological Chemistry, 1985, 260, 15232-8.	1.6	75
186	Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/â^' cells. Oncogene, 2002, 21, 4050-4059.	2.6	74
187	A mouse model of cardiac rhabdomyoma generated by loss of Tsc1 in ventricular myocytes. Human Molecular Genetics, 2005, 14, 429-435.	1.4	74
188	Functional assessment of variants in the TSC1 and TSC2 genes identified in individuals with Tuberous Sclerosis Complex. Human Mutation, 2011, 32, 424-435.	1.1	73
189	Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex. Human Molecular Genetics, 2011, 20, 4597-4604.	1.4	73
190	Advillin (p92): a new member of the gelsolin/villin family of actin regulatory proteins. Journal of Cell Science, 1998, 111, 2129-2136.	1.2	72
191	nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. Journal of Clinical Oncology, 2021, 39, 3660-3670.	0.8	69
192	Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases. Clinical Cancer Research, 2018, 24, 2182-2193.	3.2	68
193	The actin-binding proteins adseverin and gelsolin are both highly expressed but differentially localized in kidney and intestine. Journal of Cell Science, 1998, 111, 3633-3643.	1.2	68
194	Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. Clinical Cancer Research, 2001, 7, 2415-24.	3.2	67
195	Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer. Cancer Research, 2017, 77, 6987-6998.	0.4	65
196	Estrogen-induced Smooth Muscle Cell Growth Is Regulated by Tuberin and Associated with Altered Activation of Platelet-derived Growth Factor Receptor-Î² and ERK-1/2. Journal of Biological Chemistry, 2004, 279, 23114-23122.	1.6	64
197	Arp2/3 complex-deficient mouse fibroblasts are viable and have normal leading-edge actin structure and function. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16263-16268.	3.3	64
198	Clinical, Neuropathological and Genetic Aspects of the Tuberous Sclerosis Complex. Brain Pathology, 1995, 5, 173-179.	2.1	63

#	Article	IF	Citations
199	Single-Nucleotide Polymorphisms in the Interleukin-10 Gene: Differences in Frequencies, Linkage Disequilibrium Patterns, and Haplotypes in Three United States Ethnic Groups. Genomics, 2002, 80, 223-228.	1.3	63
200	Selective Inhibition of Growth of Tuberous Sclerosis Complex 2â€“Null Cells by Atorvastatin Is Associated with Impaired Rheb and Rho GTPase Function and Reduced mTOR/S6 Kinase Activity. Cancer Research, 2007, 67, 9878-9886.	0.4	63
201	Atherosclerosis. Journal of the American College of Cardiology, 2007, 49, 1589-1599.	1.2	63
202	Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma. Clinical Cancer Research, 2014, 20, 1873-1883.	3.2	63
203	Single-Cell Transcriptomic Analysis Identifies a Unique Pulmonary Lymphangioleiomyomatosis Cell. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1373-1387.	2.5	63
204	Influence of Genetic Variation in the C-Reactive Protein Gene on the Inflammatory Response During and After Acute Coronary Ischemia. Annals of Human Genetics, 2006, 70, 705-716.	0.3	61
205	Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. Journal of Experimental Medicine, 2014, 211, 15-28.	4.2	60
206	Localization of gelsolin proximal to ABL on chromosome 9. American Journal of Human Genetics, 1988, 42, 565-72.	2.6	60
207	Rapamycin-Insensitive Up-Regulation of MMP2 and Other Genes in Tuberous Sclerosis Complex 2â€“Deficient Lymphangioleiomyomatosis-Like Cells. American Journal of Respiratory Cell and Molecular Biology, 2010, 42, 227-234.	1.4	59
208	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. British Journal of Cancer, 2020, 122, 555-563.	2.9	59
209	Probing the phosphoinositide 4,5-bisphosphate binding site of human profilin I. Chemistry and Biology, 1998, 5, 273-281.	6.2	58
210	Exonic Mutations of TSC2/TSC1 Are Common but Not Seen in All Sporadic Pulmonary Lymphangioleiomyomatosis. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 663-665.	2.5	58
211	Localization of one gene for tuberous sclerosis within 9q32-9q34, and further evidence for heterogeneity. American Journal of Human Genetics, 1991, 49, 764-72.	2.6	58
212	Perturbed IFN-Î³-Jak-Signal Transducers and Activators of Transcription Signaling in Tuberous Sclerosis Mouse Models. Cancer Research, 2004, 64, 3436-3443.	0.4	56
213	Distinct Biochemical Characteristics of the Two Human Profilin Isoforms. FEBS Journal, 1995, 229, 621-628.	0.2	56
214	AMP-Activated Protein Kinase Signaling Results in Cytoplasmic Sequestration of p27. Cancer Research, 2008, 68, 6496-6506.	0.4	55
215	Angiomyolipoma Have Common Mutations in TSC2 but No Other Common Genetic Events. PLoS ONE, 2011, 6, e24919.	1.1	54
216	Comprehensive mutational analysis of the TSC1 gene: observations on frequency of mutation, associated features, and nonpenetrance. Annals of Human Genetics, 1998, 62, 277-285.	0.3	53

#	Article	IF	Citations
217	Animal Models of Lymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Complex (TSC). Lymphatic Research and Biology, 2010, 8, 51-57.	0.5	53
218	Chromosome 12q harbors multiple genetic loci related to asthma and asthma-related phenotypes. Human Molecular Genetics, 2003, 12, 1973-1979.	1.4	52
219	Autophagy-Dependent Metabolic Reprogramming Sensitizes TSC2-Deficient Cells to the Antimetabolite 6-Aminonicotinamide. Molecular Cancer Research, 2014, 12, 48-57.	1.5	52
220	Impairment of gamma-glutamyl transferase 1 activity in the metabolic pathogenesis of chromophobe renal cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6274-E6282.	3.3	52
221	Qualitative and quantitative effects of APOE genetic variation on plasma C-reactive protein, LDL-cholesterol, and apoE protein. Genes and Immunity, 2006, 7, 211-219.	2.2	51
222	TSC2 pathogenic variants are predictive of severe clinical manifestations in TSC infants: results of the EPISTOP study. Genetics in Medicine, 2020, 22, 1489-1497.	1.1	51
223	CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. Clinical Cancer Research, 2021, 27, 4025-4035.	3.2	51
224	Subependymal giant cell astrocytomas in Tuberous Sclerosis Complex have consistent TSC1/TSC2 biallelic inactivation, and no BRAF mutations. Oncotarget, 2017, 8, 95516-95529.	0.8	49
225	Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Nonâ€“Muscle-Invasive Bladder Cancer. Cancer Research, 2020, 80, 4476-4486.	0.4	49
226	Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation. Journal of Clinical Investigation, 2016, 127, 349-364.	3.9	49
227	Association between a High-Expressing Interferon-Î³ Allele and a Lower Frequency of Kidney Angiomyolipomas in TSC2 Patients. American Journal of Human Genetics, 2002, 71, 750-758.	2.6	48
228	Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycin. Human Molecular Genetics, 2011, 20, 1290-1305.	1.4	48
229	<scp>TSC1</scp> involvement in bladder cancer: diverse effects andÂtherapeutic implications. Journal of Pathology, 2013, 230, 17-27.	2.1	48
230	TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene, 2010, 29, 1588-1597.	2.6	47
231	Molecular Basis of Giant Cells in Tuberous Sclerosis Complex. New England Journal of Medicine, 2014, 371, 778-780.	13.9	47
232	Coding and small non-coding transcriptional landscape of tuberous sclerosis complex cortical tubers: implications for pathophysiology and treatment. Scientific Reports, 2017, 7, 8089.	1.6	47
233	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunology Research, 2020, 8, 1075-1084.	1.6	47
234	In vivo analysis of functional domains from villin and gelsolin.. Journal of Cell Biology, 1992, 116, 1145-1155.	2.3	46

#	Article	IF	Citations
235	Pulmonary Vascular Permeability and Ischemic Injury in Gelsolin-Deficient Mice. American Journal of Respiratory Cell and Molecular Biology, 2003, 28, 478-484.	1.4	46
236	Membrane ruffling, macropinocytosis and antigen presentation in the absence of gelsolin in murine dendritic cells. European Journal of Immunology, 1999, 29, 3450-3455.	1.6	45
237	A shower of second hit events as the cause of multifocal renal cell carcinoma in tuberous sclerosis complex. Human Molecular Genetics, 2015, 24, 1836-1842.	1.4	45
238	Estrogen Enhances whereas Tamoxifen Retards Development of Tsc Mouse Liver Hemangioma: A Tumor Related to Renal Angiomyolipoma and Pulmonary Lymphangioleiomyomatosis. Cancer Research, 2005, 65, 2474-2481.	0.4	44
239	Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. Genetics in Medicine, 2020, 22, 709-718.	1.1	44
240	Predominant induction of gelsolin and actin-binding protein during myeloid differentiation. Journal of Biological Chemistry, 1988, 263, 13857-62.	1.6	44
241	Graded loss of tuberin in an allelic series of brain models of TSC correlates with survival, and biochemical, histological and behavioral features. Human Molecular Genetics, 2012, 21, 4286-4300.	1.4	43
242	Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference. Pediatric Neurology, 2016, 60, 1-12.	1.0	43
243	Low-level mosaicism in tuberous sclerosis complex: prevalence, clinical features, and risk of disease transmission. Genetics in Medicine, 2019, 21, 2639-2643.	1.1	43
244	Distinct clinical characteristics of Tuberous Sclerosis Complex patients with no mutation identified. Annals of Human Genetics, 2009, 73, 141-146.	0.3	42
245	Early Clinical Predictors of Autism Spectrum Disorder in Infants with Tuberous Sclerosis Complex: Results from the EPISTOP Study. Journal of Clinical Medicine, 2019, 8, 788.	1.0	42
246	Antimitogenic effects of HDL and APOE mediated by Cox-2â€“dependent IP activation. Journal of Clinical Investigation, 2004, 113, 609-618.	3.9	41
247	Genomic Organization and Chromosomal Location of MurineCdc42. Genomics, 1996, 38, 13-18.	1.3	40
248	Equivalent Benefit of Rapamycin and a Potent mTOR ATP-Competitive Inhibitor, MLN0128 (INK128), in a Mouse Model of Tuberous Sclerosis. Molecular Cancer Research, 2013, 11, 467-473.	1.5	40
249	Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma. Genetics in Medicine, 2020, 22, 1366-1373.	1.1	40
250	Identification of markers flanking the tuberous sclerosis locus on chromosome 9 (TSC1).. Journal of Medical Genetics, 1993, 30, 224-227.	1.5	39
251	RASâ€“MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFRâ€“MEK Blockade. Molecular Cancer Therapeutics, 2018, 17, 1526-1539.	1.9	39
252	Prenatal Rapamycin Results in Early and Late Behavioral Abnormalities in Wildtype C57Bl/6 Mice. Behavior Genetics, 2013, 43, 51-59.	1.4	38

#	Article	IF	Citations
253	Intrafamilial Phenotypic Variability in Tuberous Sclerosis Complex. Journal of Child Neurology, 2007, 22, 1348-1355.	0.7	37
254	Brain-expressed X-linked 2 Is Pivotal for Hyperactive Mechanistic Target of Rapamycin (mTOR)-mediated Tumorigenesis. Journal of Biological Chemistry, 2015, 290, 25756-25765.	1.6	37
255	Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer. British Journal of Cancer, 2021, 124, 1680-1689.	2.9	37
256	Actin-Binding Protein (ABP-280) Filamin Gene (FLN) Maps Telomeric to the Color Vision Locus (R/GCP) and Centromeric to G6PD in Xq28. Genomics, 1993, 17, 496-498.	1.3	36
257	COL5a1: fine genetic mapping and exclusion as candidate gene in families with nail-patella syndrome, tuberous sclerosis 1, hereditary hemorrhagic telangiectasia, and Ehlersâ€"Danlos syndrome type II. Genomics, 1995, 25, 737-739.	1.3	36
258	Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 820-824.	2.3	36
259	Fine mapping of the nail-patella syndrome locus at 9q34. American Journal of Human Genetics, 1997, 60, 133-42.	2.6	36
260	The Mouse Mammary Gland Requires the Actin-Binding Protein Gelsolin for Proper Ductal Morphogenesis. Developmental Biology, 2000, 225, 407-423.	0.9	35
261	Identification of a highly polymorphic microsatellite VNTR within the argininosuccinate synthetase locus: exclusion of the dystonia gene on 9q32-34 as the cause of dopa-responsive dystonia in a large kindred. American Journal of Human Genetics, 1991, 48, 121-8.	2.6	35
262	Evidence for genetic heterogeneity in tuberous sclerosis: one locus on chromosome 9 and at least one locus elsewhere. American Journal of Human Genetics, 1992, 51, 709-20.	2.6	35
263	Multiple Cardiac Rhabdomyomas as a Sole Symptom of Tuberous Sclerosis Complex. Journal of Child Neurology, 2005, 20, 988-989.	0.7	34
264	Interferon-Î³-Jak-Stat Signaling in Pulmonary Lymphangioleiomyomatosis and Renal Angiomyolipoma. American Journal of Respiratory Cell and Molecular Biology, 2005, 33, 227-230.	1.4	33
265	An index marker map of chromosome 9 provides strong evidence for positive interference. American Journal of Human Genetics, 1993, 53, 1279-88.	2.6	33
266	Molecular Dissection of AKT Activation in Lung Cancer Cell Lines. Molecular Cancer Research, 2013, 11, 282-293.	1.5	32
267	Phenotypic distinctions between mosaic forms of tuberous sclerosis complex. Genetics in Medicine, 2019, 21, 2594-2604.	1.1	32
268	mGluR5 Modulation of Behavioral and Epileptic Phenotypes in a Mouse Model of Tuberous Sclerosis Complex. Neuropsychopharmacology, 2018, 43, 1457-1465.	2.8	32
269	Gelsolin, a Protein That Caps the Barbed Ends and Severs Actin Filaments, Enhances the Actin-Based Motility of Listeria monocytogenes in Host Cells. Infection and Immunity, 1998, 66, 3775-3782.	1.0	31
270	Differential developmentally regulated expression of gelsolin family members in the mouse. Developmental Dynamics, 1999, 215, 297-307.	0.8	30

#	Article	IF	Citations
271	Molecular Biology of Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, 191-203.	0.9	30
272	Summary and Recommendations from the National Cancer Instituteâ€™s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 2016, 2, 165-202.	0.2	30
273	Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2. European Journal of Human Genetics, 2015, 23, 1665-1672.	1.4	29
274	Human Pluripotent Stem Cellâ€“Derived TSC2-Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangioleiomyomatosis. Cancer Research, 2017, 77, 5491-5502.	0.4	29
275	A hypomorphic allele of Tsc2 highlights the role of TSC1/TSC2 in signaling to AKT and models mild human TSC2 alleles. Human Molecular Genetics, 2009, 18, 2378-2387.	1.4	28
276	Combined CDKN1A/TP53 Mutation in Bladder Cancer Is a Therapeutic Target. Molecular Cancer Therapeutics, 2015, 14, 174-182.	1.9	28
277	Somatic mosaicism is rare in unaffected parents of patients with sporadic tuberous sclerosis. Journal of Medical Genetics, 2004, 41, e69-e69.	1.5	27
278	Tuberin and Hamartin Expression Is Reduced in the Majority of Subependymal Giant Cell Astrocytomas in Tuberous Sclerosis Complex Consistent With a Two-Hit Model of Pathogenesis. Journal of Child Neurology, 2004, 19, 102-106.	0.7	27
279	Genetic determinants of C-reactive protein in COPD. European Respiratory Journal, 2006, 28, 1156-1162.	3.1	27
280	Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer. , 2021, 9, e002917.		27
281	Renal and liver tumors in Tsc2+/â^' mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Molecular Cancer Therapeutics, 2009, 8, 1799-1807.	1.9	26
282	A High-Resolution Linkage Map of Human 9q34.1. Genomics, 1993, 17, 587-591.	1.3	25
283	Denaturing high-performance liquid chromatography (DHPLC) is a highly sensitive, semi-automated method for identifying mutations in the TSC1 gene. Journal of Proteomics, 2001, 47, 33-37.	2.4	25
284	Molecular genetic aspects of the phakomatoses: tuberous sclerosis complex and neurofibromatosis 1. Current Opinion in Neurology, 2001, 14, 163-169.	1.8	25
285	Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. Clinical Cancer Research, 2021, 27, 3845-3853.	3.2	25
286	A 37-Marker PCR-Based Genetic Linkage Map of Human Chromosome 9: Observations on Mutations and Positive Interference. Genomics, 1995, 28, 140-146.	1.3	24
287	Platelet-Derived Growth Factorâ€“Induced p42/44 Mitogen-Activated Protein Kinase Activation and Cellular Growth Is Mediated by Reactive Oxygen Species in the Absence of TSC2/Tuberin. Cancer Research, 2005, 65, 10881-10890.	0.4	24
288	Therapeutic Trial of Metformin and Bortezomib in a Mouse Model of Tuberous Sclerosis Complex (TSC). PLoS ONE, 2012, 7, e31900.	1.1	24

#	Article	IF	Citations
289	Identification of Nine Genomic Regions of Amplification in Urothelial Carcinoma, Correlation with Stage, and Potential Prognostic and Therapeutic Value. PLoS ONE, 2013, 8, e60927.	1.1	24
290	The Human Actin-Regulatory Protein Cap G: Gene Structure and Chromosome Location. Genomics, 1994, 23, 560-565.	1.3	23
291	Comprehensive mutation analysis of TSC1 using two-dimensional DNA electrophoresis with DGGE. Annals of Human Genetics, 1998, 62, 491-504.	0.3	23
292	Distinct Biochemical Characteristics of the Two Human Profilin Isoforms. FEBS Journal, 1995, 229, 621-628.	0.2	23
293	Design and Generation of MLPA Probe Sets for Combined Copy Number and Small-Mutation Analysis of Human Genes: EGFR as an Example. Scientific World Journal, The, 2010, 10, 2003-2018.	0.8	23
294	Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma. Oncogene, 2014, 33, 3151-3160.	2.6	23
295	Is autism driven by epilepsy in infants with Tuberous Sclerosis Complex?. Annals of Clinical and Translational Neurology, 2020, 7, 1371-1381.	1.7	23
296	mTORC1-S6K Activation by Endotoxin Contributes to Cytokine Up-Regulation and Early Lethality in Animals. PLoS ONE, 2010, 5, e14399.	1.1	22
297	Torsion dystonia genes in two populations confined to a small region on chromosome 9q32-34. American Journal of Human Genetics, 1991, 49, 366-71.	2.6	22
298	Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology. Genome Medicine, 2022, 14, 39.	3.6	22
299	Myelin Pathology Beyond White Matter in Tuberous Sclerosis Complex (TSC) Cortical Tubers. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1054-1064.	0.9	21
300	A genetic linkage map of human chromosome 9q. Genomics, 1992, 14, 715-720.	1.3	20
301	Cancer Genetics: TSC1, TSC2, TSC3? or mosaicism?. European Journal of Human Genetics, 2005, 13, 695-696.	1.4	20
302	Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion. Journal of Experimental Medicine, 2019, 216, 2635-2652.	4.2	20
303	Analysis of PKD1 for genomic deletion by multiplex ligation-dependent probe assay: Absence of hot spots. Genomics, 2008, 91, 203-208.	1.3	19
304	Prediction of Neurodevelopment in Infants With Tuberous Sclerosis Complex Using Early EEG Characteristics. Frontiers in Neurology, 2020, 11, 582891.	1.1	19
305	Early epileptiform EEG activity in infants with tuberous sclerosis complex predicts epilepsy and neurodevelopmental outcomes. Epilepsia, 2021, 62, 1208-1219.	2.6	19
306	Dinucleotide repeat polymorphism at the ABL locus (9q34). Nucleic Acids Research, 1991, 19, 967.	6.5	19

#	Article	IF	Citations
307	Identification of the functional profilin gene, its localization to chromosome subband 17p13.3, and demonstration of its deletion in some patients with Miller-Dieker syndrome. American Journal of Human Genetics, 1990, 46, 559-67.	2.6	19
308	A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. Clinical Cancer Research, 2002, 8, 691-7.	3.2	19
309	Functional consequences of amyloidosis mutation for gelsolin polypeptide- analysis of gelsolin-actin interaction and gelsolin processing in gelsolin knock-out fibroblasts. FEBS Letters, 1999, 454, 233-239.	1.3	18
310	Functions of [His321]Gelsolin Isolated from a Flat Revertant of ras -Transformed Cells. FEBS Journal, 1995, 229, 615-620.	0.2	18
311	Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells. Oncotarget, 2017, 8, 64714-64727.	0.8	18
312	REPORT on the Fifth International Workshop on Chromosome 9 held at Eynsham, Oxfordshire, UK, September 4â€“6, 1996. Annals of Human Genetics, 1997, 61, 183-206.	0.3	18
313	Characterisation of six large deletions in TSC2 identified using long range PCR suggests diverse mechanisms including Alu mediated recombination. Journal of Medical Genetics, 2000, 37, 877-883.	1.5	17
314	Mechanisms of gelsolin-dependent and -independent EGF-stimulated cell motility in a human lung epithelial cell line. Experimental Cell Research, 2005, 307, 153-163.	1.2	17
315	Tuberous Sclerosis Complex 1: An Epithelial Tumor Suppressor Essential to Prevent Spontaneous Prostate Cancer in Aged Mice. Cancer Research, 2010, 70, 8937-8947.	0.4	17
316	Notch transactivates Rheb to maintain the multipotency of TSC-null cells. Nature Communications, 2017, 8, 1848.	5.8	17
317	Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1. Molecular Therapy - Methods and Clinical Development, 2019, 15, 18-26.	1.8	17
318	Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin. Science Advances, 2021, 7, .	4.7	17
319	RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics. Journal of Clinical Investigation, 2021, 131, .	3.9	17
320	Rapamycin-Insensitive Up-Regulation of Adipocyte Phospholipase A2 in Tuberous Sclerosis and Lymphangioleiomyomatosis. PLoS ONE, 2014, 9, e104809.	1.1	17
321	CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer. British Journal of Cancer, 2022, 126, 797-803.	2.9	17
322	A phase II trial of cyclophosphamide, etoposide, and cisplatin with combined chest and brain radiotherapy in limited small-cell lung cancer: a Cancer and Leukemia Group B Study.. Journal of Clinical Oncology, 1987, 5, 1874-1879.	0.8	16
323	Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile. Modern Pathology, 2021, 34, 264-279.	2.9	16
324	Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway. Cell Reports, 2021, 34, 108707.	2.9	16

#	Article	IF	Citations
325	Trans-ethnic variation in germline variants of patients with renal cell carcinoma. Cell Reports, 2021, 34, 108926.	2.9	16
326	Stochastic Model of Tsc1 Lesions in Mouse Brain. PLoS ONE, 2013, 8, e64224.	1.1	16
327	Tuberous sclerosis. Archives of Dermatology, 1994, 130, 348-54.	1.7	16
328	A radiation-reduced hybrid cell line containing 5 Mb/17 cM of human DNA from 9q34. Genomics, 1992, 13, 841-844.	1.3	15
329	REPORT on the Fourth International Workshop on Chromosome 9: held at Williamsburg, Virginia, USA, April 23?25, 1995. Annals of Human Genetics, 1995, 59, 347-365.	0.3	15
330	Characterization of Gelsolin Truncates that Inhibit Actin Depolymerization by Severing Activity of Gelsolin and Cofilin. FEBS Journal, 1997, 248, 834-839.	0.2	15
331	mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses?. EBioMedicine, 2015, 2, 2-4.	2.7	15
332	Inhibition of MAPK pathway is essential for suppressing Rheb-Y35N driven tumor growth. Oncogene, 2017, 36, 756-765.	2.6	15
333	TSC2 regulates microRNA biogenesis via mTORC1 and GSK3Î². Human Molecular Genetics, 2018, 27, 1654-1663.	1.4	15
334	Cell crawling two decades after Abercrombie. Biochemical Society Symposia, 1999, 65, 267-80.	2.7	15
335	Molecular biology of gelsolin, a calcium-regulated actin filament severing protein. Biorheology, 1987, 24, 643-647.	1.2	14
336	Tuberous sclerosis complex neuropathology requires glutamate-cysteine ligase. Acta Neuropathologica Communications, 2015, 3, 48.	2.4	14
337	Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model. Neurobiology of Disease, 2015, 82, 22-31.	2.1	14
338	Pancreatic PEComa is a novel member of the family of tuberous sclerosis complex-associated tumors: case report and review of the literature. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 707-710.	1.4	14
339	Tuberin Regulates Prostaglandin Receptorâ€“Mediated Viability, via Rheb, in mTORC1-Hyperactive Cells. Molecular Cancer Research, 2017, 15, 1318-1330.	1.5	14
340	Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genetics, 2018, 14, e1007679.	1.5	14
341	MITF is a driver oncogene and potential therapeutic target in kidney angiomyolipoma tumors through transcriptional regulation of CYR61. Oncogene, 2021, 40, 112-126.	2.6	14
342	A tissue-bioengineering strategy for modeling rare human kidney diseases in vivo. Nature Communications, 2021, 12, 6496.	5.8	14

#	Article	IF	Citations
343	1O Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC. Annals of Oncology, 2021, 32, S1373.	0.6	13
344	Identification of a transcriptional profile associated with in vitro invasion in non-small cell lung cancer cell lines. Cancer Biology and Therapy, 2004, 3, 624-631.	1.5	12
345	Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. European Urology Focus, 2016, 2, 633-639.	1.6	12
346	SNP identification, haplotype analysis, and parental origin of mutations in TSC2. Human Genetics, 2002, 111, 96-101.	1.8	11
347	A Vascular Model of Tsc1 Deficiency Accelerates Renal Tumor Formation with Accompanying Hemangiosarcomas. Molecular Cancer Research, 2015, 13, 548-555.	1.5	11
348	Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Molecular Cancer Therapeutics, 2020, 19, 690-696.	1.9	11
349	The gelsolin (GSN) cDNA clone, from 9q32-34, identifies Bell and StuI RFLPs. Nucleic Acids Research, 1989, 17, 4425-4425.	6.5	10
350	Rapamycin-Resistant Poly (ADP-Ribose) Polymerase-1 Overexpression Is a Potential Therapeutic Target in Lymphangioleiomyomatosis. American Journal of Respiratory Cell and Molecular Biology, 2014, 51, 738-749.	1.4	10
351	Lymphangioleiomyomatosis Association with Underlying Genotype in Patients with Tuberous Sclerosis Complex. Annals of the American Thoracic Society, 2021, 18, 815-819.	1.5	10
352	Dinucleotide repeat polymorphism at the GSN locus (9q32-34). Nucleic Acids Research, 1991, 19, 967.	6.5	10
353	Induction of Apoptosis by Gelsolin Truncates. Annals of the New York Academy of Sciences, 1999, 886, 217-220.	1.8	9
354	A 34 bp Deletion Within TSC2 is a Rare Polymorphism, not a Pathogenic Mutation. Annals of Human Genetics, 2003, 67, 495-503.	0.3	9
355	Pivotal role of augmented Î±B-crystallin in tumor development induced by deficient TSC1/2 complex. Oncogene, 2014, 33, 4352-4358.	2.6	9
356	Nipple Angiofibromas with Loss of TSC2 Are Associated with Tuberous Sclerosis Complex. Journal of Investigative Dermatology, 2016, 136, 535-538.	0.3	9
357	Exclusion of the gelsolin gene on 9q32-34 as the cause of familial lattice corneal dystrophy type I. American Journal of Human Genetics, 1992, 51, 156-60.	2.6	9
358	Three independent mutations in the TSC2 gene in a family with tuberous sclerosis. European Journal of Human Genetics, 2009, 17, 1165-1170.	1.4	8
359	Therapeutic Targeting of DGKA-Mediated Macropinocytosis Leads to Phospholipid Reprogramming in Tuberous Sclerosis Complex. Cancer Research, 2021, 81, 2086-2100.	0.4	8
360	Cosmid Contigs from the Tuberous Sclerosis Candidate Region on Chromosome 9q34. European Journal of Human Genetics, 1995, 3, 78-86.	1.4	8

#	Article	IF	Citations
361	Association of Early MRI Characteristics With Subsequent Epilepsy and Neurodevelopmental Outcomes in Children With Tuberous Sclerosis Complex. Neurology, 2022, 98, .	1.5	8
362	A 5.4-Mb Continuous Pulsed-Field Gel Electrophoresis Map of Human 9q34.1 between ABL and D9S114, Including the Tuberous Sclerosis (TSC1) Region. Genomics, 1995, 28, 105-108.	1.3	7
363	Lack of Association Between Genetic Variation in 9 Innate Immunity Genes and Baseline CRP Levels. Annals of Human Genetics, 2006, 70, 574-586.	0.3	7
364	The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer. European Urology Focus, 2015, 1, 94-95.	1.6	7
365	Celecoxib in lymphangioleiomyomatosis: results of a phase I clinical trial. European Respiratory Journal, 2020, 55, 1902370.	3.1	7
366	Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer. PLoS ONE, 2021, 16, e0248380.	1.1	7
367	Results of quantitative EEG analysis are associated with autism spectrum disorder and development abnormalities in infants with tuberous sclerosis complex. Biomedical Signal Processing and Control, 2021, 68, 102658.	3.5	7
368	FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma. BJUI Compass, 2022, 3, 169-172.	0.7	7
369	Pulmonary cysts consistent with lymphangioleiomyomatosis are common in women with tuberous sclerosis: genetic and radiographic analysis. Chest, 2002, 121, 61S.	0.4	7
370	Targeted deletion of Tsc1 causes fatal cardiomyocyte hyperplasia independently of afterload. Cardiovascular Pathology, 2015, 24, 80-93.	0.7	6
371	Apparent Sporadic Lymphangioleiomyomatosis (LAM) in a Man Due to Extreme Mosaicism for a TSC2Mutation. Annals of the American Thoracic Society, 2017, 14, 1227-1229.	1.5	6
372	Failure of gelsolin overexpression to regulate lymphocyte apoptosis. Blood, 2000, 95, 3483-8.	0.6	6
373	Ultrasensitive profiling of UV-induced mutations identifies thousands of subclinical facial tumors in tuberous sclerosis complex. Journal of Clinical Investigation, 2022, 132, .	3.9	6
374	Regional Localization of 64 Cosmid Contigs, Including 18 Genes and 14 Markers, to Intervals on Human Chromosome 9q34. Genomics, 1995, 29, 257-260.	1.3	5
375	Human XPMC2H: cDNA Cloning, Mapping to 9q34, Genomic Structure, and Evaluation as TSC1. Genomics, 1997, 44, 350-354.	1.3	5
376	Magnetic Resonance Imaging and Characterization of Spontaneous Lesions in a Transgenic Mouse Model of Tuberous Sclerosis as a Model for Endothelial Cell-Based Transgene Delivery. Human Gene Therapy, 2005, 16, 1367-1376.	1.4	5
377	Seizures in tuberous sclerosis complex: hitting the target. Lancet, The, 2016, 388, 2062-2064.	6.3	5
378	Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2018, 16, 341-348.	0.9	5

#	Article	IF	Citations
379	A novel mouse model of hemangiopericytoma due to loss of Tsc2. Human Molecular Genetics, 2018, 27, 4169-4175.	1.4	5
380	A diagnostic algorithm for enhanced detection of mosaic tuberous sclerosis complex in adults. British Journal of Dermatology, 2020, 182, 235-237.	1.4	5
381	Long-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy â€“ tuberous sclerosis complex. Impact, 2019, 2019, 6-9.	0.0	5
382	Generalised mosaicism for TSC2 mutation in isolated lymphangioleiomyomatosis. European Respiratory Journal, 2019, 54, 1900938.	3.1	5
383	Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 669-677.	0.6	5
384	MicroRNAâ€34a activation in tuberous sclerosis complex during early brain development may lead to impaired corticogenesis. Neuropathology and Applied Neurobiology, 2021, 47, 796-811.	1.8	5
385	Cloning and evaluation of RALGDS as a candidate for the tuberous sclerosis gene TSC1. Annals of Human Genetics, 1997, 61, 299-305.	0.3	5
386	Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. JCO Precision Oncology, 2022, 6, e2100448.	1.5	5
387	Analysis of a Mouse Skin Model of Tuberous Sclerosis Complex. PLoS ONE, 2016, 11, e0167384.	1.1	4
388	MCL1 and DEDD Promote Urothelial Carcinoma Progression. Molecular Cancer Research, 2019, 17, 1294-1304.	1.5	4
389	Down-regulation of the brain-specific cell-adhesion molecule contactin-3 in tuberous sclerosis complex during the early postnatal period. Journal of Neurodevelopmental Disorders, 2022, 14, 8.	1.5	4
390	Functions of [His321]Gelsolin Isolated from a Flat Revertant of ras â€Transformed Cells. FEBS Journal, 1995, 229, 615-620.	0.2	3
391	Lymphangioleiomyomatosis: Cause of a Malignant Chylous Pleural Effusion. Journal of Clinical Oncology, 2010, 28, e4-e6.	0.8	3
392	Facing Uncertainty. New England Journal of Medicine, 2019, 381, 2253-2259.	13.9	3
393	Membrane ruffling, macropinocytosis and antigen presentation in the absence of gelsolin in murine dendritic cells. , 1999, 29, 3450.		3
394	Evolution of electroencephalogram in infants with tuberous sclerosis complex and neurodevelopmental outcome: a prospective cohort study. Developmental Medicine and Child Neurology, 2022, 64, 495-501.	1.1	3
395	The spontaneous coat color mutant white nose (wn) maps to murine Chromosome 15. Mammalian Genome, 1999, 10, 750-752.	1.0	2
396	Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. JCO Precision Oncology, 2018, 2, 1-11.	1.5	2

#	Article	IF	Citations
397	The Codon 72 TP53 Polymorphism Contributes to TSC Tumorigenesis through the Notchâ€“Nodal Axis. Molecular Cancer Research, 2019, 17, 1639-1651.	1.5	2
398	Targeting Molecular Aberrations in Urothelial Carcinoma: Are We Almost There?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 195-199.	1.8	2
399	Dinucleotide repeat polymorphism at the D9S112 locus (9q31-34). Nucleic Acids Research, 1992, 20, 930.	6.5	2
400	nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program.. Journal of Clinical Oncology, 2022, 40, 11574-11574.	0.8	2
401	Expression of gelsolin by cos cell secretion. Cytoskeleton, 1989, 14, 21-25.	4.4	1
402	Potential location of a bladder tumor suppressor gene on chromosome 9q at 9q13 to 9q22.1. Urologic Oncology: Seminars and Original Investigations, 1995, 1, 88-92.	0.8	1
403	Leydig Cell Tumor of the Testis in Tuberous Sclerosis: Lack of Second Hit Events. Oncologist, 2012, 17, 927-929.	1.9	1
404	A biomarker for lymphangioleiomyomatosis. Lancet Respiratory Medicine,the, 2013, 1, 424-425.	5.2	1
405	Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434â€“5. European Urology, 2020, 77, 436-438.	0.9	1
406	Sporadic facial angiofibroma and sporadic angiomyolipoma mimicking tuberous sclerosis complex. Journal of Medical Genetics, 2021, , jmedgenet-2021-108160.	1.5	1
407	A subgroup of lymphangioleiomyomatosis with no TSC mutations identified. FASEB Journal, 2012, 26, lb498.	0.2	1
408	Dinucleotide repeat polymorphism at the D9S116 locus (9q31-34). Nucleic Acids Research, 1992, 20, 931.	6.5	1
409	Dinucleotide repeat polymorphism at the D9S117 locus (9q31-34). Nucleic Acids Research, 1992, 20, 931.	6.5	1
410	Dinucleotide repeat polymorphism at the D9S119 locus (9q22-34). Nucleic Acids Research, 1992, 20, 932.	6.5	1
411	Dinucleotide repeat polymorphism at the D9S121 locus (9q31-34). Nucleic Acids Research, 1992, 20, 933.	6.5	1
412	Treatment of refractory lymphangioleiomyomatosisâ€“associated chylous effusion with a pleuroperitoneal window and omental flap. Journal of Thoracic and Cardiovascular Surgery, 2009, 138, 497-498.	0.4	0
413	Sequential Response to FGFR3 Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With FGFR3-TACC3 Fusionâ€“Positive Metastatic Urothelial Carcinoma. JCO Precision Oncology, 2018, 2, 1-6.	1.5	0
414	Long-term therapeutic efficacy of intravenous AAV-mediated hamartin replacement in mouse model of tuberous sclerosis type 1. IBRO Reports, 2019, 6, S504.	0.3	0

#	Article	IF	Citations
415	Abstract 1026: Bi-steric mTORC1-selective inhibitors demonstrate improved potency and efficacy in tumors with mTORC1 hyperactivation. , 2021, , .		0
416	Molecular Diagnostics of Genetic Diseases: Experience from Studies of DMD, APC, TSC1, and OPG Genes. Part 2.. Journal of Clinical Biochemistry and Nutrition, 2000, 28, 129-141.	0.6	0
417	Impaired Viability, Platelet Survival, Morphology and Function in Mice Lacking Filamin A.. Blood, 2006, 108, 391-391.	0.6	0
418	Abstract B09: Aspirin inhibits cyclooxygenase 2-mediated prostaglandin production and tumorigenesisin a preclinical model of tuberous sclerosis complex. , 2014, , .		0
419	First Results of the EPISTOP Study. , 2019, 50, .		0
420	Dinucleotide repeat polymorphism at the D9S115 locus (9q31-34). Nucleic Acids Research, 1992, 20, 930.	6.5	0
421	Dinucleotide repeat polymorphism at the D9S118 locus (9q31-34). Nucleic Acids Research, 1992, 20, 932.	6.5	0
422	Dinucleotide repeat polymorphism at the D9S120 locus (9q31-34). Nucleic Acids Research, 1992, 20, 933.	6.5	0